secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001628280-26-014987
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026
------------------------------------------------------------------------------

- Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.
- Cash and investments at Dec 31, 2025 were $78.1M; after $21.4M ATM raise in Q1 2026, pro forma cash ~$94.5M.
- SL-325 Phase 1 in healthy volunteers nearly complete; data expected Q2 2026, Phase 2 in Crohn's planned Q3 2026.
- R&D expenses fell to $35.3M from $67.2M, driven by discontinuation of SL-172154 program.
- Michael Choi, M.D., appointed VP of Clinical Development; cash runway guidance extended into 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/0001628280-26-014987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/sttk-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-014987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer